An Open-label, Single-arm, Multicenter Phase I/II Clinical Study of SHR-4375 Injection in Patients With Advanced Solid Tumors to Evaluate Safety, Tolerability, Pharmacokinetics and Efficacy
Latest Information Update: 28 Jan 2025
Price :
$35 *
At a glance
- Drugs SHR 4375 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Suzhou Suncadia Biopharmaceuticals
- 22 Jan 2025 Status changed from not yet recruiting to recruiting.
- 16 Jan 2025 New trial record